Search 

Company:
Maculus Therapeutix is a preclinical-stage biopharmaceutical company focused on finding practical solutions to treat chronic diseases of the retina and optic nerve such as wetAMD (Age related Macular Degeneration) in the Ophthalmology space with a novel tunable biodegradable proprietary product – MacuBloc™ capable of delivering any FDA approved drugs for Wet AMD to the site of the disease. With its unique suitability for targeted and extended delivery of drugs to back of the human eyes, MacuBloc™ offers significant benefits to Wet AMD patients over existing products: a single intravitreal injection that lasts an year instead of the current 10-12 monthly injections plus significant potential reduction in inflammation, infection, doctor visits and total cost of care compared to current practice.

Market:
The global market size of Age-Related Macular Degeneration (AMD) is currently $7.7B, growing at 7.6% CAGR and is expected to reach a value of $11B by 2025. Current standard of care involves 10-12 monthly injections with a 30 gauge syringe needle going through the eye sclera, often resulting post-injection pain and possible infection due to repeated injections in a small area as well as ruptured blood vessels in the sclera. By reducing the number of injections from 10+ to just ONE, MacuBloc™ formulation is likely to be a treatment of choice.

Medical Research and Development of innovative Products.Currently developed the Worlds 1st Hydroxychloroquine Sulfate based pMDI/ Medical micro dose as an Inhaler Therapeutic/Prophylactic to combat SARs CoVid2

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.

Trading in Pharmaceuticals and Medical Devices and Medical consumable products in United Arab Emirated

A CAP, CLIA And AABB certified clinical lab specialized in genetic and molecular diagnosis

Medprin focuses on RD and sales and marketing of implantable medical devices with products in general surgery and neurosurgery. Current Medprin is actively looking for promising startups /team with matching technology/products that Medprin can both invests financially and develops long term partnership.

MedSci Healthcare was established in 2002 with the creation of Bioon.com, with headquarters in Shanghai and internationally in the U.S. We are committed to be the bridge between China and the U.S. healthcare. This is done by connecting Chinese healthcare professionals (HCPs) with U.S. resources and vice versa.
The company has done projects with major companies such as: Pfizer, Harvard Medical School, AstraZeneca, GSK, Abbott, Johnson & Johnson, Takeda, Novartis, Medtronic and many more. We have also worked with organizations such as the China Cardiovascular Association (CCA), Chinese Medical Doctor Association (CMDA) and more.
MedSci is a digital academic platform, scientific publishing support and multichannel marketing (MCM) organization. We use the term Academic Promotion Organization (APO). We use scientific writers, doctors & researcher scientists and commercialization experts to develop customized strategy & implementation to reach each organization’s goals.

Biopharmaceutical